Grail multicancer detection test wins FDA advisers’ backing
Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Grail's cancer blood test faces high-stakes FDA review medicalxpress.com
- FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance qz.com
- This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval marketwatch.com
- Grail’s cancer blood test faces high-stakes FDA review winnipegfreepress.com
- GRAIL's Galleri test wins endorsement from FDA panel seekingalpha.com
